Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

NCT07711210 is registered in ClinicalTrials.gov with Jiangsu Aidea Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07711210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07711210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of the ACC017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV-1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Lead sponsor
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 21, 2025
Completion date
December 30, 2027
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus